J&J Nipocalimab granted U.S. FDA Priority Review for generalized myasthenia gravis

 Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study

Results demonstrate sustained disease control over 24 weeks in a broad population of antibody positive adult patients: anti-AChR, anti-MuSK, anti-LRP4

https://www.easternprogress.com/nipocalimab-granted-u-s-fda-priority-review-for-the-treatment-of-generalized-myasthenia-gravis/article_cf282bcf-9203-5b96-86e7-3e55b261f358.html